PL2271670T3 - Testy aktywności serotypu A toksyny botulinowej oparte na immunologii - Google Patents

Testy aktywności serotypu A toksyny botulinowej oparte na immunologii

Info

Publication number
PL2271670T3
PL2271670T3 PL09719709T PL09719709T PL2271670T3 PL 2271670 T3 PL2271670 T3 PL 2271670T3 PL 09719709 T PL09719709 T PL 09719709T PL 09719709 T PL09719709 T PL 09719709T PL 2271670 T3 PL2271670 T3 PL 2271670T3
Authority
PL
Poland
Prior art keywords
immuno
botulinum toxin
activity assays
toxin serotype
based botulinum
Prior art date
Application number
PL09719709T
Other languages
English (en)
Inventor
Ester Fernandez-Salas
Joanne Wang
Patton E Garay
Lina S Wong
D Dianne Hodges
Kei Roger Aoki
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40677745&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2271670(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PL2271670T3 publication Critical patent/PL2271670T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/085—Picornaviridae, e.g. coxsackie virus, echovirus, enterovirus
    • C07K14/10—Hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/952—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
PL09719709T 2008-03-14 2009-03-13 Testy aktywności serotypu A toksyny botulinowej oparte na immunologii PL2271670T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3672308P 2008-03-14 2008-03-14
PCT/US2009/037046 WO2009114748A1 (en) 2008-03-14 2009-03-13 Immuno-based botulinum toxin serotype a activity assays
EP09719709.9A EP2271670B1 (en) 2008-03-14 2009-03-13 Immuno-based botulinum toxin serotype a activity assays

Publications (1)

Publication Number Publication Date
PL2271670T3 true PL2271670T3 (pl) 2015-05-29

Family

ID=40677745

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16153819T PL3031825T3 (pl) 2008-03-14 2009-03-13 Immunologiczne oznaczenie aktywności toksyny botulinowej serotypu a
PL09719709T PL2271670T3 (pl) 2008-03-14 2009-03-13 Testy aktywności serotypu A toksyny botulinowej oparte na immunologii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16153819T PL3031825T3 (pl) 2008-03-14 2009-03-13 Immunologiczne oznaczenie aktywności toksyny botulinowej serotypu a

Country Status (26)

Country Link
US (11) US8198034B2 (pl)
EP (6) EP4588519A3 (pl)
JP (5) JP5766954B2 (pl)
KR (1) KR101609894B1 (pl)
CN (2) CN102356091A (pl)
AU (1) AU2009223161B2 (pl)
BR (2) BR122012027456A2 (pl)
CA (1) CA2715033C (pl)
CO (1) CO6311001A2 (pl)
CY (2) CY1115771T1 (pl)
DK (2) DK3031825T3 (pl)
ES (2) ES2524312T3 (pl)
HR (1) HRP20191886T1 (pl)
HU (1) HUE046037T2 (pl)
IL (2) IL208097A (pl)
LT (1) LT3031825T (pl)
MX (1) MX2010010137A (pl)
MY (2) MY165032A (pl)
NZ (1) NZ588029A (pl)
PL (2) PL3031825T3 (pl)
PT (2) PT3031825T (pl)
RU (2) RU2491293C2 (pl)
SG (1) SG2014009112A (pl)
SI (2) SI3031825T1 (pl)
UA (1) UA102247C2 (pl)
WO (1) WO2009114748A1 (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP2246426A4 (en) * 2008-01-29 2011-08-10 Inst Antibodies Co Ltd COMPOSITION FOR THE NEUTRALIZATION OF BOTULINUS TOXIN TYPE-A AND HUMAN ANTIBODIES AGAINST BOTULINUS TOXIN TYPE-A
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101604515B1 (ko) * 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
WO2010105236A1 (en) 2009-03-13 2010-09-16 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
AU2015203359A1 (en) * 2009-03-13 2015-07-02 Allergan, Inc. Cells useful for immuno-based Botulinum toxin serotype A activity assays
CN102439138B (zh) 2009-03-13 2018-03-30 阿勒根公司 可用于基于免疫的肉毒杆菌毒素血清a型活性测定的细胞
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
WO2011022438A2 (en) * 2009-08-18 2011-02-24 Us Army Medical Research And Materiel Command Cleavage sensitive antibodies and methods of use thereof
BR112012011675A2 (pt) * 2009-11-18 2016-07-05 Merz Pharma Gmbh & Co Kgaa método de medição de um efeito induzido a um tecido celular e a um tecido muscular por uma neurotoxina clostridial, seu uso e produto de programa de computador
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
US9303285B2 (en) 2012-01-04 2016-04-05 Biomadison, Inc. Methods and compounds for increasing sensitivity of botulinum assays
US10908146B2 (en) 2011-06-01 2021-02-02 Biomadison, Inc. Compositions and methods for improving sensitivity in cell based assays
KR101679370B1 (ko) 2011-06-01 2016-11-24 바이오메디슨, 인코퍼레이티드 비-ｆｒｅｔ 보툴리눔 검정법
KR101640694B1 (ko) 2011-09-29 2016-07-18 셀스냅, 엘엘씨 독소생산능 시험용 조성물 및 방법
CA2854857C (en) * 2011-11-25 2020-01-07 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Monoclonal antibody for the detection of snap/clip tag
EP2798077A2 (en) * 2011-12-31 2014-11-05 Allergan, Inc. Highly Sensitive Cell-Based Assay to Detect the Presence of Active Botulinum Neurotoxin Serotype-A
KR102168506B1 (ko) * 2012-01-04 2020-10-21 바이오메디슨, 인코퍼레이티드 보툴리눔 분석 감도를 증진시키기 위한 방법 및 화합물
WO2014060373A1 (en) 2012-10-16 2014-04-24 Merz Pharma Gmbh & Co. Kgaa Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
CN111454931A (zh) * 2012-11-21 2020-07-28 益普生生物创新有限公司 用于制备经蛋白水解处理的多肽的方法
US20140170132A1 (en) 2012-12-18 2014-06-19 Allergan, Inc. Prophylatic treatment of herpes recurrence
JP6608357B2 (ja) 2013-06-28 2019-11-20 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 細胞において神経毒ポリペプチドの生物活性を決定する手段及び方法
LT3270162T (lt) 2013-08-09 2020-09-10 Biomadison, Inc. Padidinto jautrumo botulino toksino tyrimas
US10408837B2 (en) * 2013-12-09 2019-09-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Peptide substrates recognizable by type E botulinum neurotoxin
CA2947006A1 (en) 2014-04-30 2015-11-05 Eric A. Forssen Formulations of biologics for intravesical instillation
ES2642916T3 (es) 2014-06-06 2017-11-20 Galit KLEINER-FISMAN Toxina botulínica para su uso en el tratamiento de la paratonia
SG10201913979VA (en) 2014-07-07 2020-03-30 Allergan Inc Method of detecting cleaved snap25 in tissue samples
EP3567055A1 (en) 2014-07-07 2019-11-13 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
KR20220048046A (ko) 2014-07-31 2022-04-19 알러간, 인코포레이티드 방광내 주입을 위한 생물학 제형
KR102409293B1 (ko) 2014-11-21 2022-06-14 메르츠 파마 게엠베하 운트 코. 카가아 신경독소 폴리펩티드의 생물학적 활성의 측정 방법
AU2015367329B2 (en) * 2014-12-19 2021-02-18 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
RU2694820C9 (ru) 2014-12-23 2019-08-12 Мерц Фарма Гмбх Унд Ко. Кгаа Контейнер, предварительно заполненный ботулиновым токсином
EP3240566B1 (en) * 2014-12-31 2020-07-22 Development Center for Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
US9527922B2 (en) 2014-12-31 2016-12-27 Development Center For Biotechnology Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
TWI704156B (zh) * 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法
JP6412471B2 (ja) 2015-07-15 2018-10-24 富士フイルム株式会社 含窒素複素環化合物の製造方法およびその中間体
WO2017049251A2 (en) * 2015-09-18 2017-03-23 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
ES2893838T3 (es) 2016-03-02 2022-02-10 Merz Pharma Gmbh & Co Kgaa Composición que comprende toxina botulínica
TWI737742B (zh) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素的預填充式注射器系統、具有其之套組以及其之使用
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
IL265109B2 (en) 2016-09-13 2024-05-01 Allergan Inc Stabilized non-protein clostridial toxin compositions
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
EP3333179A1 (en) 2016-12-07 2018-06-13 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum toxin with accelarated onset of effect
EP3335719A1 (en) 2016-12-14 2018-06-20 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with a stabilized light chain
IL268688B2 (en) 2017-03-24 2024-01-01 Merz Pharma Gmbh & Co Kgaa Improved use of botulinum neurotoxin in the treatment of sialorrhea
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
US20210008156A1 (en) 2017-10-26 2021-01-14 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019101308A1 (en) 2017-11-22 2019-05-31 Merz Pharma Gmbh & Co. Kgaa Novel recombinant botulinum toxin with increased duration of effect
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
JP6544669B1 (ja) 2018-03-16 2019-07-17 ディヴェロップメント センター フォー バイオテクノロジー アルファエノラーゼに特異的な抗体及びその使用
WO2020070017A1 (en) 2018-10-02 2020-04-09 Merz Pharma Gmbh & Co. Kgaa Novel uses of botulinum neurotoxin for treating lipoedema
EP3660509B1 (en) 2018-11-29 2022-03-09 Hugel Inc. A cell-based method for determining an activity of botulinum toxin
KR102251096B1 (ko) * 2018-12-12 2021-05-13 휴젤(주) 보툴리눔 독소 활성을 결정하는 세포 기반 방법
KR101983216B1 (ko) * 2018-11-29 2019-05-29 주식회사 에이비바이오 보툴리눔 독소 활성을 결정하기 위한 항체, 및 이를 이용한 활성 측정방법
JP7646555B2 (ja) 2019-02-21 2025-03-17 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン 振戦治療のためのボツリヌス神経毒素の新規用途
KR102274841B1 (ko) * 2019-10-16 2021-07-12 주식회사 하울바이오 Snare 복합체를 억제하는 항-snap 25 항체 및 이의 용도
KR20230020961A (ko) 2020-06-05 2023-02-13 메르츠 파마 게엠베하 운트 코. 카가아 안면 주름의 고용량 및 저용적 보툴리눔 독소 치료
US20220010355A1 (en) * 2020-07-10 2022-01-13 Galderma Holding SA Cell based method for determination of botulinum toxin potency based on western blotting
KR102797145B1 (ko) * 2021-05-24 2025-04-22 주식회사 에이티지씨 렌티바이러스에 의해 특정 유전자가 삽입된 보툴리눔 독소에 민감한 세포
EP4349992A4 (en) * 2021-05-24 2025-09-24 Atgc Co Ltd BOTULINUM TOXIN-SENSITIVE CELLS INTO WHICH A SPECIFIC GENE HAS BEEN INSERTED BY A LENTIVIRUS
KR20240141340A (ko) 2022-02-15 2024-09-26 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소 액체 제형 및 그 용도
MX2024009969A (es) 2022-02-15 2024-09-18 Merz Pharma Gmbh & Co Kgaa Formulacion liquida de toxina botulinica y uso de la misma.
TW202400122A (zh) 2022-02-28 2024-01-01 德商梅茲製藥有限兩合公司 肉毒桿菌毒素用於降低皮膚毛孔尺寸及／或皮脂產生之用途、以及降低皮膚毛孔尺寸及／或皮脂產生的方法
US20260092255A1 (en) * 2022-04-21 2026-04-02 Biomadison, Inc. Cell Based Assays for Botulinum
EP4615489A1 (en) 2022-11-07 2025-09-17 Allergan, Inc. Prevention of post-operative atrial fibrillation with a botulinum toxin
WO2024115413A1 (en) 2022-11-28 2024-06-06 Merz Pharma Gmbh & Co. Kgaa High concentration botulinum toxin treatment for neck rejuvenation
AU2023400491A1 (en) 2022-11-28 2025-04-10 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin injection in platysma for lower face and neck rejuvenation
EP4633596A1 (en) 2022-12-15 2025-10-22 Merz Pharma GmbH & Co. KGaA Injectable gel comprising botulinum toxin and uses thereof
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
KR20260002664A (ko) 2023-03-15 2026-01-06 메르츠 파마 게엠베하 운트 코. 카가아 적어도 하나의 유체 샘플을 처리하기 위한 록킹 셰이커
WO2024194181A1 (en) 2023-03-20 2024-09-26 Merz Therapeutics GmbH Nh3 scavenger for use in the treatment of mobility disability in a post-stroke patient
WO2024240868A1 (en) 2023-05-23 2024-11-28 Merz Therapeutics GmbH Botulinum toxin for treating peripheral neuropathic pain
CN121511091A (zh) 2023-07-12 2026-02-10 莫茨药物股份两合公司 通过肉毒杆菌毒素的色素沉着过度病况治疗
IL326140A (en) 2023-08-10 2026-03-01 Merz Pharma Gmbh & Co Kgaa Liquid formulation of botulinum toxin and its use
DE102025101336A1 (de) 2024-01-19 2025-07-24 Abbvie Inc. Zusammensetzungen von clostridium botulinum neurotoxin serotyp a und verbesserte trocknungsprozesse
WO2025228877A1 (en) 2024-04-29 2025-11-06 Merz Therapeutics GmbH Botulinum toxin for the preventive treatment of migraine
WO2026021713A1 (en) 2024-07-23 2026-01-29 Merz Therapeutics GmbH Uses of magnetic nerve stimulation associated with botulinum neurotoxin administration

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3672308A (en) 1970-11-06 1972-06-27 Westinghouse Electric Corp Roadway switching arrangement for transportation system having center guiderail below track level
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5955584A (en) * 1986-03-31 1999-09-21 Charter Ventures Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
EP0517805B1 (en) 1990-02-26 2002-07-10 The Board Of Trustees Of The Leland Stanford Junior University Identification and expression of insect steroid receptor dna sequences
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5962255A (en) 1992-03-24 1999-10-05 Cambridge Antibody Technology Limited Methods for producing recombinant vectors
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US5364791A (en) 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
WO1994000481A1 (en) 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
SE9304060D0 (sv) 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager
US5962637A (en) 1994-06-03 1999-10-05 Microbiological Research Authority Toxin assay
GB9411138D0 (en) * 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
ATE266726T1 (de) * 1995-06-07 2004-05-15 Ortho Pharma Corp CDR-TRANSPLANTIERTE ANTIKÖRPER GEGEN ßTISSUE FACTORß UND VERFAHREN ZUR DEREN VERWENDUNG
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US6072041A (en) 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
TR200002885T2 (tr) * 1998-04-03 2000-12-21 Chugai Seiyaku Kabushiki Kaisha İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP1137664A2 (en) 1998-12-10 2001-10-04 Washington University Protein transduction system and methods of use thereof
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
DE60032367T3 (de) 1999-08-25 2011-03-10 Allergan, Inc., Irvine Aktivierbare rekombinante neurotoxine
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
GB9930519D0 (en) 1999-12-24 2000-02-16 Phogen Limited Uses of transport proteins
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US6294553B1 (en) 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6325899B1 (en) 2000-03-10 2001-12-04 Action Caps, Llc Disposable and recyclable intermediates for use in electrostatic coating processes
JP5610659B2 (ja) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US20030219462A1 (en) 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US6841535B2 (en) 2000-07-31 2005-01-11 Active Motif Peptide-mediated transfection agents and methods of use
US6678651B2 (en) * 2000-09-15 2004-01-13 Mindspeed Technologies, Inc. Short-term enhancement in CELP speech coding
CA2428270C (en) * 2000-11-06 2013-07-02 Leonard A. Smith Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US8022172B2 (en) 2001-08-28 2011-09-20 Allergan, Inc. Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7208285B2 (en) 2001-08-28 2007-04-24 Allergan, Inc. Fret protease assays for botulinum serotype A/E toxins
US20080064054A1 (en) * 2001-08-28 2008-03-13 Ester Fernandez-Salas Fluorescence resonance energy transfer (fret) assays for clostridial toxin activity
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
AU2002360377A1 (en) * 2001-11-09 2003-05-19 The Ohio State University Research Foundation Baalc expression as a diagnostic marker for acute leukemia
AU2003216389A1 (en) 2002-02-21 2003-09-09 Essentia Biosystems, Inc. Induction of hair growth with vascular endothelial growth factor
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
RU2230325C2 (ru) * 2002-08-15 2004-06-10 Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации Способ приготовления очищенного препарата ботулинического токсина типа а
US7183066B2 (en) 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
US7166692B2 (en) 2003-03-04 2007-01-23 Canbrex Bio Science Walkersville, Inc. Intracellular delivery of small molecules, proteins, and nucleic acids
WO2005030119A2 (en) * 2003-04-11 2005-04-07 Allergan, Inc. Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
WO2005076785A2 (en) * 2003-12-19 2005-08-25 Wisconsin Alumni Research Foundation Method and compositions for detecting botulinum neurotoxin
US8497081B2 (en) * 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
DK1718756T3 (da) * 2004-02-24 2012-02-27 Allergan Inc Botulinumtoksinscreeningassays
CA2558408C (en) 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
AU2011253597B2 (en) 2004-03-03 2014-12-04 Revance Therapeutics, Inc. Multi-component biological transport systems
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
WO2005118582A1 (ja) 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7906276B2 (en) * 2004-06-30 2011-03-15 Kimberly-Clark Worldwide, Inc. Enzymatic detection techniques
US7399607B2 (en) 2004-09-22 2008-07-15 Allergan, Inc. Fluorescence polarization assays for determining clostridial toxin activity
US20070258992A1 (en) * 2004-10-06 2007-11-08 Atassi M Zouhair Determining and Reducing Immunoresistance to Botulinum Toxin Therapy Using Botulinum Toxin a Peptides
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
WO2006094263A2 (en) 2005-03-03 2006-09-08 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2006099590A2 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE602006017237D1 (en) * 2005-04-05 2010-11-11 Allergan Inc Clostridientoxinaktivitätstests
ATE552500T1 (de) * 2005-04-05 2012-04-15 Allergan Inc Lipophile, farbstoffbasierte fret-assays für die clostridientoxinaktivität
ATE555387T1 (de) 2005-10-12 2012-05-15 Allergan Inc Tests der molekularen oder subzellulären nähe unter verwendung von depolarisierung nach resonanzenergietransfer (daret)
NZ568216A (en) 2005-11-17 2012-09-28 Revance Therapeutics Inc Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
GB2437311A (en) * 2006-04-07 2007-10-24 Mologic Ltd A protease detection product
US8796429B2 (en) 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
SG158112A1 (en) * 2006-06-02 2010-01-29 Aveo Pharmaceuticals Inc Hepatocyte growth factor (hgf) binding proteins
CA2658260A1 (en) 2006-07-11 2008-01-17 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
MY142256A (en) 2006-09-14 2010-11-15 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
CN100577149C (zh) * 2006-12-21 2010-01-06 北京民海生物科技有限公司 一种治疗用a型肉毒毒素冻干粉针剂新型冻干保护剂配方
WO2008082885A2 (en) 2006-12-29 2008-07-10 Revance Therapeutics, Inc. Transport molecules using reverse sequence hiv-tat polypeptides
AU2007340162B2 (en) 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
US8753831B2 (en) * 2007-06-05 2014-06-17 City Of Hope Methods for detection of botulinum neurotoxin
HRP20161722T1 (hr) 2007-07-26 2017-02-10 Revance Therapeutics, Inc. Antimikrobni peptid i njegovi pripravci
US20100227868A1 (en) 2007-09-20 2010-09-09 Johnson Brent A Treatment methods with brimonidine
US8198034B2 (en) 2008-03-14 2012-06-12 Allergan, Inc. Immuno-based botulinum toxin serotype A activity assays
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
ES2669020T3 (es) 2008-12-31 2018-05-23 Revance Therapeutics, Inc. Formulaciones inyectables de toxina botulínica
CN102439138B (zh) * 2009-03-13 2018-03-30 阿勒根公司 可用于基于免疫的肉毒杆菌毒素血清a型活性测定的细胞
WO2010105236A1 (en) * 2009-03-13 2010-09-16 Allergan, Inc. Immuno-based retargeted endopeptidase activity assays
LT5982B (lt) * 2012-04-24 2013-12-27 Uab Friday Lab Su planšetiniu kompiuteriu arba išmaniuoju telefonu suderintas žuvų ieškiklis
WO2014060373A1 (en) * 2012-10-16 2014-04-24 Merz Pharma Gmbh & Co. Kgaa Cellular test systems for the determination of the biological activities of neurotoxin polypeptides
US20160289731A1 (en) * 2012-11-21 2016-10-06 Merz Pharma Gmbh & Co, Kgaa Means and methods for determination of botulinum neurotoxin biological activity
EP3567055A1 (en) * 2014-07-07 2019-11-13 Allergan, Inc. Method of detecting cleaved snap25 in tissue samples
AU2015367329B2 (en) * 2014-12-19 2021-02-18 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of BoNT/E in cells
TWI704156B (zh) * 2015-03-04 2020-09-11 德商曼茲法瑪股份有限公司 用於增進肉毒桿菌神經毒素進入細胞之特定攝取的方法

Also Published As

Publication number Publication date
HK1225746A1 (en) 2017-09-15
WO2009114748A1 (en) 2009-09-17
CN102937653A (zh) 2013-02-20
IL208097A (en) 2015-10-29
CO6311001A2 (es) 2011-08-22
US20200392212A1 (en) 2020-12-17
US20210171614A1 (en) 2021-06-10
JP2015143689A (ja) 2015-08-06
PT3031825T (pt) 2019-10-31
KR20100139022A (ko) 2010-12-31
PT2271670E (pt) 2014-11-28
SG2014009112A (en) 2014-04-28
DK2271670T3 (en) 2014-12-01
JP5766954B2 (ja) 2015-08-19
US11261240B2 (en) 2022-03-01
IL222737A0 (en) 2012-12-31
CA2715033C (en) 2014-11-25
SI3031825T1 (sl) 2019-12-31
US20120122128A1 (en) 2012-05-17
EP3556770A1 (en) 2019-10-23
CY1115771T1 (el) 2017-01-25
MY155049A (en) 2015-08-28
AU2009223161A1 (en) 2009-09-17
EP2578601A1 (en) 2013-04-10
NZ588029A (en) 2012-12-21
AU2009223161B2 (en) 2014-10-30
BR122012027456A2 (pt) 2015-07-14
EP2271670B1 (en) 2014-09-03
US20200369749A1 (en) 2020-11-26
MY165032A (en) 2018-02-28
US8198034B2 (en) 2012-06-12
JP2015214567A (ja) 2015-12-03
JP2011526243A (ja) 2011-10-06
CN102937653B (zh) 2015-09-09
US10703806B2 (en) 2020-07-07
UA102247C2 (ru) 2013-06-25
BRPI0908578A2 (pt) 2014-10-29
DK3031825T3 (da) 2019-10-28
RU2012146463A (ru) 2014-05-10
SI2271670T1 (sl) 2015-01-30
ES2755505T3 (es) 2020-04-22
RU2491293C2 (ru) 2013-08-27
US20120225436A1 (en) 2012-09-06
MX2010010137A (es) 2010-10-25
KR101609894B1 (ko) 2016-04-08
CN102356091A (zh) 2012-02-15
EP3031825B1 (en) 2019-07-24
HRP20191886T1 (hr) 2019-12-27
RU2010140478A (ru) 2012-04-20
JP2018049020A (ja) 2018-03-29
US20130040368A1 (en) 2013-02-14
EP2271670A1 (en) 2011-01-12
JP6227597B2 (ja) 2017-11-08
IL222737A (en) 2015-10-29
ES2524312T3 (es) 2014-12-05
JP6050401B2 (ja) 2016-12-21
US20170283487A1 (en) 2017-10-05
EP4588519A2 (en) 2025-07-23
IL208097A0 (en) 2010-12-30
EP4588519A3 (en) 2025-10-15
US9249216B2 (en) 2016-02-02
PL3031825T3 (pl) 2020-02-28
HK1151298A1 (en) 2012-01-27
CY1122328T1 (el) 2021-01-27
LT3031825T (lt) 2020-02-10
US20210340229A1 (en) 2021-11-04
HUE046037T2 (hu) 2020-01-28
EP3031825A1 (en) 2016-06-15
US20230235031A1 (en) 2023-07-27
US11332518B2 (en) 2022-05-17
US20230279083A1 (en) 2023-09-07
JP2013100304A (ja) 2013-05-23
CA2715033A1 (en) 2009-09-17
EP3851451A1 (en) 2021-07-21
US20220144925A1 (en) 2022-05-12
JP6522075B2 (ja) 2019-05-29

Similar Documents

Publication Publication Date Title
IL222737A0 (en) Immuno - based botulinum toxin serotype a activity assays
IL240785A0 (en) Cells useful for immunoassays of botulinum toxin type a activity
PL2406629T3 (pl) Immunologiczne oznaczenia endopeptydazy o przekierowanej aktywności
AP2010005424A0 (en) Assays.
IL211552A0 (en) Improved antibody libraries
PL2164862T3 (pl) Toksyna netb z clostridium
PL2370713T3 (pl) Dwudyskowy zawór zasuwowy
BRPI0822713A2 (pt) Método de produção de toxina clostridium botulinum
GB2461506B (en) A seal arrangement
IL189149A (en) Botulinum nerve toxin a
PL2248826T3 (pl) Przeciwciało skierowane przeciwko PcrV
GB0818726D0 (en) A seal
EP2309135A4 (en) SERVO-VALVE
GB0816918D0 (en) A seal
IL219259A0 (en) Assay for quantifying clostridial neurotoxin
GB0816915D0 (en) A seal
GB0712641D0 (en) Predictive operation
AU2008901359A0 (en) Movement Analysis
GB0716770D0 (en) Movement detection
GB0801931D0 (en) A seal
GB0801929D0 (en) A SEal
PH32008000237S1 (en) Gate valve
ZA201101226B (en) A loyalty system